Skip to main content
Top
Published in: Respiratory Research 1/2011

Open Access 01-12-2011 | Research

High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial

Authors: Amit K Mahajan, Gregory B Diette, Umur Hatipoğlu, Andrew Bilderback, Alana Ridge, Vanessa Walker Harris, Vijay Dalapathi, Sameer Badlani, Stephanie Lewis, Jeff T Charbeneau, Edward T Naureckas, Jerry A Krishnan

Published in: Respiratory Research | Issue 1/2011

Login to get access

Abstract

Background

High frequency chest wall oscillation (HFCWO) is used for airway mucus clearance. The objective of this study was to evaluate the use of HFCWO early in the treatment of adults hospitalized for acute asthma or chronic obstructive pulmonary disease (COPD).

Methods

Randomized, multi-center, double-masked phase II clinical trial of active or sham treatment initiated within 24 hours of hospital admission for acute asthma or COPD at four academic medical centers. Patients received active or sham treatment for 15 minutes three times a day for four treatments. Medical management was standardized across groups. The primary outcomes were patient adherence to therapy after four treatments (minutes used/60 minutes prescribed) and satisfaction. Secondary outcomes included change in Borg dyspnea score (≥ 1 unit indicates a clinically significant change), spontaneously expectorated sputum volume, and forced expired volume in 1 second.

Results

Fifty-two participants were randomized to active (n = 25) or sham (n = 27) treatment. Patient adherence was similarly high in both groups (91% vs. 93%; p = 0.70). Patient satisfaction was also similarly high in both groups. After four treatments, a higher proportion of patients in the active treatment group had a clinically significant improvement in dyspnea (70.8% vs. 42.3%, p = 0.04). There were no significant differences in other secondary outcomes.

Conclusions

HFCWO is well tolerated in adults hospitalized for acute asthma or COPD and significantly improves dyspnea. The high levels of patient satisfaction in both treatment groups justify the need for sham controls when evaluating the use of HFCWO on patient-reported outcomes. Additional studies are needed to more fully evaluate the role of HFCWO in improving in-hospital and post-discharge outcomes in this population.

Trial Registration

ClinicalTrials.gov: NCT00181285
Appendix
Available only for authorised users
Literature
1.
go back to reference Castro M, Zimmerman N, Crocker S, et al: Asthma intervention program prevents readmission in high healthcare utilizers. Am J Respir Crit Care Med. 2003, 168: 1094-1099.CrossRef Castro M, Zimmerman N, Crocker S, et al: Asthma intervention program prevents readmission in high healthcare utilizers. Am J Respir Crit Care Med. 2003, 168: 1094-1099.CrossRef
2.
go back to reference Bloomberg G, Trinkaus K, Fisher E, et al: Hospital readmission for childhood asthma: A 10-year metropolitan study. Am J Respir Crit Care Med. 2003, 167: 1068-1076. 10.1164/rccm.2201015.CrossRefPubMed Bloomberg G, Trinkaus K, Fisher E, et al: Hospital readmission for childhood asthma: A 10-year metropolitan study. Am J Respir Crit Care Med. 2003, 167: 1068-1076. 10.1164/rccm.2201015.CrossRefPubMed
3.
go back to reference Rowe B, Bota G, Fabris L, et al: Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department. JAMA. 1999, 281: 2119-2126. 10.1001/jama.281.22.2119.CrossRefPubMed Rowe B, Bota G, Fabris L, et al: Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department. JAMA. 1999, 281: 2119-2126. 10.1001/jama.281.22.2119.CrossRefPubMed
4.
go back to reference Niewoehner D, Erbland M, Deupree R, et al: Effect of systemic glucocorticoids on exacerbations of chronic obstructive lung disease. N Engl J Med. 1999, 340: 1941-1947. 10.1056/NEJM199906243402502.CrossRefPubMed Niewoehner D, Erbland M, Deupree R, et al: Effect of systemic glucocorticoids on exacerbations of chronic obstructive lung disease. N Engl J Med. 1999, 340: 1941-1947. 10.1056/NEJM199906243402502.CrossRefPubMed
5.
go back to reference Garcia-Aymerich J, Farrero E, Felez M, et al: Risk factors for readmission to hospital for a copd exacerbation: A prospective study. Thorax. 2003, 58: 100-105. 10.1136/thorax.58.2.100.CrossRefPubMedPubMedCentral Garcia-Aymerich J, Farrero E, Felez M, et al: Risk factors for readmission to hospital for a copd exacerbation: A prospective study. Thorax. 2003, 58: 100-105. 10.1136/thorax.58.2.100.CrossRefPubMedPubMedCentral
6.
go back to reference Mannino D, Homa D, Akinbami L, Ford E, Redd S: Chronic obstructive pulmonary disease surveillance - - - United States, 1971-2000. National Center of Health Statistics. 2002 Mannino D, Homa D, Akinbami L, Ford E, Redd S: Chronic obstructive pulmonary disease surveillance - - - United States, 1971-2000. National Center of Health Statistics. 2002
7.
go back to reference Carroll N, Mutavdic S, James A: Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax. 2002, 47: 5- Carroll N, Mutavdic S, James A: Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax. 2002, 47: 5-
8.
go back to reference Kuyper L, Pare P, Hogg J, Lambert R, Ionescu D, Woods R, Bai T: Characterization of airway plugging in fatal asthma. Am J Med. 2003, 115: 6-11.CrossRefPubMed Kuyper L, Pare P, Hogg J, Lambert R, Ionescu D, Woods R, Bai T: Characterization of airway plugging in fatal asthma. Am J Med. 2003, 115: 6-11.CrossRefPubMed
9.
go back to reference Tanizaki Y, Kitani H, Okazaki M, Mifune T, Mitsunobu F, Kimura I: Mucus hypersecretion and eosinophils in bronchoalveolar lavage fluid in patients with bronchial asthma. J Asthma. 1993, 30: 5-10.3109/02770909309066375.CrossRef Tanizaki Y, Kitani H, Okazaki M, Mifune T, Mitsunobu F, Kimura I: Mucus hypersecretion and eosinophils in bronchoalveolar lavage fluid in patients with bronchial asthma. J Asthma. 1993, 30: 5-10.3109/02770909309066375.CrossRef
10.
go back to reference Rogers D, Barnes P: Treatment of airway mucus hypersecretion. Annals of Medicine. 2006, 38: 9-CrossRef Rogers D, Barnes P: Treatment of airway mucus hypersecretion. Annals of Medicine. 2006, 38: 9-CrossRef
11.
go back to reference Linhartova A, Anderson A, Foraker A: Intraluminal exudates of nonrespiratory bronchioles in pulmonary emphysema. Human Pathology. 1971, 2: 3-CrossRef Linhartova A, Anderson A, Foraker A: Intraluminal exudates of nonrespiratory bronchioles in pulmonary emphysema. Human Pathology. 1971, 2: 3-CrossRef
12.
go back to reference Arens R, Gozal D, Omlin K, Vega J, Boyd K, Keens T, Woo M: Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med. 1994, 150: 1154-1157.CrossRefPubMed Arens R, Gozal D, Omlin K, Vega J, Boyd K, Keens T, Woo M: Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med. 1994, 150: 1154-1157.CrossRefPubMed
13.
go back to reference Fink J, Mahlmeister M: High-frequency oscillation of the airway and chest wall. Respir Care. 2002, 47: 797-807.PubMed Fink J, Mahlmeister M: High-frequency oscillation of the airway and chest wall. Respir Care. 2002, 47: 797-807.PubMed
14.
go back to reference Hansen L, Warwick W: High-frequency chest compression system to aid in clearance of mucus from the lung. Biomed Instrum Technol. 1990, 24: 289-294.PubMed Hansen L, Warwick W: High-frequency chest compression system to aid in clearance of mucus from the lung. Biomed Instrum Technol. 1990, 24: 289-294.PubMed
15.
go back to reference Lange D, Lechtzin N, Davey C, David W, Heiman-Patteron T, Gelinas D, Becker B, Mitsumoto H: High-frequency chest wall oscillation in ALS: An exploratory randomized, controlled trial. Neurology. 2006, 67: 6-10.1212/01.wnl.0000229468.02136.f6.CrossRef Lange D, Lechtzin N, Davey C, David W, Heiman-Patteron T, Gelinas D, Becker B, Mitsumoto H: High-frequency chest wall oscillation in ALS: An exploratory randomized, controlled trial. Neurology. 2006, 67: 6-10.1212/01.wnl.0000229468.02136.f6.CrossRef
16.
go back to reference Morrison L, Agnew J: Oscillation devices for airway clearance in people with cystic fibrosis. Cochran Database of Systemic Reviews 2009. 2010, CD006842- Morrison L, Agnew J: Oscillation devices for airway clearance in people with cystic fibrosis. Cochran Database of Systemic Reviews 2009. 2010, CD006842-
20.
go back to reference Ries AL: Minimally clinically important difference for the UCSD shortness of breath questionnaire, borg scale, and visual analog scale. COPD. 2005, 2: 105-110. 10.1081/COPD-200050655.CrossRefPubMed Ries AL: Minimally clinically important difference for the UCSD shortness of breath questionnaire, borg scale, and visual analog scale. COPD. 2005, 2: 105-110. 10.1081/COPD-200050655.CrossRefPubMed
21.
go back to reference Sutherland ER: Sham procedure versus usual care as the control in clinical trials of devices. Proc Am Thorac. 2007, 4: 574-576. 10.1513/pats.200707-090JK.CrossRef Sutherland ER: Sham procedure versus usual care as the control in clinical trials of devices. Proc Am Thorac. 2007, 4: 574-576. 10.1513/pats.200707-090JK.CrossRef
22.
go back to reference Al-Mutairi S, Sharma P, Al-Alawi A, Al-Deen J: Impulse oscillometry: An alternative modality to the conventional pulmonary function test to categorise obstructive pulmonary disorders. Clin Exp Med. 2007, 7: 8-CrossRef Al-Mutairi S, Sharma P, Al-Alawi A, Al-Deen J: Impulse oscillometry: An alternative modality to the conventional pulmonary function test to categorise obstructive pulmonary disorders. Clin Exp Med. 2007, 7: 8-CrossRef
Metadata
Title
High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial
Authors
Amit K Mahajan
Gregory B Diette
Umur Hatipoğlu
Andrew Bilderback
Alana Ridge
Vanessa Walker Harris
Vijay Dalapathi
Sameer Badlani
Stephanie Lewis
Jeff T Charbeneau
Edward T Naureckas
Jerry A Krishnan
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2011
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-12-120

Other articles of this Issue 1/2011

Respiratory Research 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.